| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2785093 | Current Opinion in Genetics & Development | 2010 | 4 Pages |
Abstract
The phosphoinositide 3-kinase (PI3K) pathway is activated in a variety of different human cancers, and inhibitors of this pathway are under active development as anti-cancer therapeutics. In this review, we discuss the data supporting the use of PI3K pathway inhibitors in genetically and clinically defined cancers. This review focuses on their efficacy as single agents and in combination with other targeted therapies, specifically those targeting the MEK–ERK signaling pathway.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Developmental Biology
Authors
Kwok-Kin Wong, Jeffrey A Engelman, Lewis C Cantley,